2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999

• December 11, 2003
  Cypress Bioscience, Inc. Announces Milnacipran Clinical Study Results Demonstrating that Effective Treatment of Fibromylagia-Related Pain is Distinct from the Treatment of Mood
• November 12, 2003
  Cypress Bioscience, Inc. Announces Third Quarter 2003 Results
• October 28, 2003
  Cypress Bioscience Presents Data at the American College of Rheumatology Annual Meeting Demonstrating Benefits of Milnacipran for Fibromyalgia Patients Using Several Measurements of Pain
• October 23, 2003
  Cypress Bioscience, Inc. Broadens its Intellectual Property Position with Receipt of New U.S. Patent for the Use of Milnacipran in the Treatment of Chronic Fatigue Syndrome and Pain
• October 21, 2003
  Cypress Bioscience, Inc. Announces Launch of Phase III Milnacipran Program With Fibromyalgia Patients
• October 1, 2003
  Cypress Bioscience, Inc. Calls for Redemption Outstanding Warrants Issued in Connection with March 2002 Private Placement
• August 14, 2003
  Cypress Bioscience, Inc. Announces Second Quarter 2003 Results
• August 5, 2003
  Cypress Bioscience, Inc. Expands Intellectual Property Portfolio with Receipt of New U.S. Patent for the Use of Milnacipran in the Treatment of Fibromyalgia Syndrome
• June 25, 2003
  Cypress Bioscience Holds Kick-Off Meeting for New Clinical Study Using Milnacipran to Treat Irritable Bowel Syndrome
• June 19, 2003
  Cypress Bioscience’s Study Design Used as a Model for Pain Assessment in Clinical Trials
• June 9, 2003
  Cypress Bioscience Revises Milnacipran License with Pierre Fabre Médicament to Improve Economic Terms and Expand the Licensed Field
• May 29, 2003
  Cypress Bioscience Drug Milnacipran May Act through Multiple Mechanisms New Data Suggests Distinct Effects on Pain and Mood
• May 16, 2003
  Cypress Bioscience Drug Milnacipran Demonstrates Efficacy in Cognitive Performance Animal Model
• May 15, 2003
  Cypress Bioscience, Inc. Announces First Quarter 2003 Results
• May 13, 2003
  Cypress Bioscience Drug Candidate, Milnacipran, Highlighted in Newsweek Magazine ARticle on Fibromyalgia Syndrome
• April 7, 2003
  Cypress Bioscience, Inc. Closes $10.3 Million Financing Funds Will be Used to Advance the Company’s FMS and Related Initiatives
• March 27, 2003
  Cypress Bioscience, Inc. Enters Into Agreements for Private Placement of Approximately $10.3 Million
• March 24, 2003
  Cypress Bioscience, Inc. Announces Results Demonstrating the Superiority of Electronic Diary as a Method to Record Pain Assessments
• March 21, 2003
  Cypress Bioscience, Inc. Announces Final Results of Milnacipran Phase II Clinical Trial in Fibromyalgia
• March 20, 2003
  Cypress Bioscience, Inc. Announces Fourth Quarter and Fiscal Year End 2002 Results
• February 10, 2003
  Cypress Bioscience, Inc.’s Announces Topline Final Results of Milnacipran Phase II Study in Fibromyalgia Syndrome